Literature DB >> 19850429

Applications of a planar electrochemiluminescence platform to support regulated studies of macromolecules: benefits and limitations in assay range.

Theingi Thway1, Chris Macaraeg, Dominador Calamba, Vimal Patel, Jennifer Tsoi, Mark Ma, Jean Lee, Binodh Desilva.   

Abstract

Development and validation of ligand binding methods that can measure therapeutic antibodies (TA) accurately and precisely are essential for bioanalysis that supports regulated pharmacokinetic (PK) and toxicokinetic (TK) studies. Non-bead (planar) electrochemiluminescence (ECL) methods are known to have high sensitivity and a wide assay range and are therefore potentially useful in supporting research studies in the early phases of development as well as for diagnostic fields and multiplex biomarker applications. Here, we demonstrate the applications for using ECL for regulated studies associated with protein drug development. Three planar ECL methods were developed, validated, and implemented to quantify three different TAs to support PK/TK studies. An automated liquid handler was used for the preparation of standards, quality controls, and validation samples to minimize assay variability. Robustness and ruggedness were tested during pre-study validations. During method optimization, the potential assay ranges were 3 log orders. To improve assay accuracy and precision, assay ranges in all 3 methods were truncated by at least 50% at the upper end before proceeding to pre-study validations. All 3 methods had assay ranges of about 2 logs during pre-study validations. The inter-assay accuracy and precision during pre-study validations were <6% and 8%, respectively. The total error of the assays was <15% for both in-study and pre-study validations in all 3 methods. With the incorporation of a robotic workstation we concluded that performance in all 3 planar ECL methods was extremely precise and accurate during pre-study and in-study validations, enabling >90% assay success during sample analyses. Although there were limitations in the assay ranges, the strength of this technology in assay accuracy, precision, and reproducibility can be beneficial for macromolecule analyses in support of PK and TK studies in a regulated environment.

Mesh:

Substances:

Year:  2009        PMID: 19850429     DOI: 10.1016/j.jpba.2009.09.035

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  5 in total

1.  Assessment of incurred sample reanalysis for macromolecules to evaluate bioanalytical method robustness: effects from imprecision.

Authors:  Theingi M Thway; Michael Eschenberg; Dominador Calamba; Chris Macaraeg; Mark Ma; Binodh DeSilva
Journal:  AAPS J       Date:  2011-04-03       Impact factor: 4.009

2.  In Silico Evaluation of the Potential Impact of Bioanalytical Bias Difference between Two Therapeutic Protein Formulations for Pharmacokinetic Assessment in a Biocomparability Study.

Authors:  Theingi M Thway; Chris Macaraeg; Michael Eschenberg; Mark Ma
Journal:  AAPS J       Date:  2015-03-05       Impact factor: 4.009

3.  Retrospective Analysis of Bioanalytical Method Validation Approaches in Biosimilar Biological Product Development.

Authors:  O N Obianom; Theingi M Thway; S J Schrieber; O O Okusanya; Y M Wang; S M Huang; I Zineh
Journal:  AAPS J       Date:  2019-09-11       Impact factor: 4.009

4.  Key amino acid residues of ankyrin-sensitive phosphatidylethanolamine/phosphatidylcholine-lipid binding site of βI-spectrin.

Authors:  Marcin Wolny; Michał Grzybek; Ewa Bok; Anna Chorzalska; Marc Lenoir; Aleksander Czogalla; Klaudia Adamczyk; Adam Kolondra; Witold Diakowski; Michael Overduin; Aleksander F Sikorski
Journal:  PLoS One       Date:  2011-06-28       Impact factor: 3.240

5.  A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.

Authors:  Niels Kruse; Michael G Schlossmacher; Walter J Schulz-Schaeffer; Eugeen Vanmechelen; Hugo Vanderstichele; Omar M El-Agnaf; Brit Mollenhauer
Journal:  PLoS One       Date:  2016-04-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.